Journal profile · ONCOLOGY-GENETICS & HEREDITY
Cancer Genomics & Proteomics
ISSN 1109-6535 · eISSN 1790-6245 · International Institute of Anticancer Research · GREECE
Cancer Genomics & Proteomics: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.54; fully open access; median 43 days to acceptance (99 articles, last 24 months); 63 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Genomics & Proteomics is published by International Institute of Anticancer Research and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Ferroptosis and cancer prognosis and Cancer-related molecular mechanisms research, together about 23.2% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.
Source: LetPub
Research area (LetPub): ONCOLOGY-GENETICS & HEREDITY
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology9.8%
- Ferroptosis and cancer prognosisMedicine8%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.4%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology5.3%
- Cancer Cells and MetastasisMedicine5%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology4.8%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.5%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Genetics & Heredity | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Genetics & Heredity | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.54LetPub ·
- CiteScore 2026-06
- 4.9LetPub ·
- SJR 2026-06
- 0.81LetPub ·
- SNIP 2026-06
- 0.67LetPub ·
- h-index
- 32LetPub ·
- h-index
- 38OpenAlex ·
- i10-index
- 263OpenAlex ·
- 2-year mean citedness
- 2.06OpenAlex ·
- Self-citation rate
- 11.5%LetPub ·
- Share of gold OA articles
- 99.5%LetPub ·
Volume
- Articles per year
- 77LetPub ·
Articles by year OpenAlex count · 619 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 60 | 60 | 20 |
| 2025 | 63 | 63 | 124 |
| 2024 | 60 | 60 | 233 |
| 2023 | 66 | 66 | 444 |
| 2022 | 60 | 60 | 669 |
| 2021 | 71 | 71 | 1,000 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
43 daysMedian, submission to acceptance · P25–P75 34 days – 56 days
- Acceptance to online
- median 52 days (10 articles)
- Submission to online
- median 91 days
- Sample
- 99 articles with submission and acceptance dates (146 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- International Institute of Anticancer Research
- Country or region
- GREECE
- Language
- English
- ISSN
- 1109-6535
- Electronic ISSN
- 1790-6245
- Latest issue on the website
- Volume 23, Issue 5 (October 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cancer Genomics & Proteomics
What CAS zone is Cancer Genomics & Proteomics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Genomics & Proteomics is in Zone 4 of Medicine, and in Zone 3 of the minor category Genetics & Heredity / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Genomics & Proteomics?
The latest impact factor listed by LetPub is 2.54; CiteScore 4.9, h-index 38.
How long does peer review take at Cancer Genomics & Proteomics?
Based on the dates recorded on 99 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 43 days (interquartile range 34–56 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Cancer Genomics & Proteomics?
According to LetPub and DOAJ records, Cancer Genomics & Proteomics is indexed in SCIE and Scopus.
Is Cancer Genomics & Proteomics open access, and what is the APC?
Cancer Genomics & Proteomics is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .